Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 14/20 | 0.83 |
| ▸ | PTGES | O14684 | 1/20 | 0.69 |
| ▸ | PPARG | P37231 | 3/20 | 0.59 |
| ▸ | PPARA | Q07869 | 2/20 | 0.59 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.59 |
| ▸ | AKT1 | P31749 | 2/20 | 0.56 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.56 |
| ▸ | PHLPP1 | O60346 | 1/20 | 0.56 |
| ▸ | ILK | Q13418 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29465604 | 1.00 | ALOX5 (0.83) | ALOX5PTGESPPARGPPARANR1I2 | |
| Gamma-Tocotrienol SCHEMBL16430897 | 1.00 | ALOX5 (0.83) | ALOX5PTGESPPARGPPARANR1I2 | |
| Gamma-Tocotrienol SCHEMBL3270920 | 1.00 | ALOX5 (0.83) | ALOX5PTGESPPARGPPARANR1I2 | |
| Gamma-Tocotrienol SCHEMBL3270923 | 1.00 | ALOX5 (0.83) | ALOX5PTGESPPARGPPARANR1I2 | |
| Gamma-Tocotrienol SCHEMBL29354672 | 1.00 | ALOX5 (0.83) | ALOX5PTGESPPARGPPARANR1I2 | |
| SCHEMBL17523133 | 0.93 | ALOX5 (0.71) | ALOX5PTGESPPARGPPARANR1I2 | |
| SCHEMBL12368109 | 0.93 | ALOX5 (0.71) | ALOX5PTGESPPARGPPARANR1I2 | |
| SCHEMBL18583914 | 0.93 | ALOX5 (0.88) | ALOX5PTGESPPARGPPARANR1I2 | |
| SCHEMBL18583915 | 0.91 | ALOX5 (1.00) | ALOX5PTGESPPARGPPARANR1I2 | |
| SCHEMBL16589599 | 0.90 | ALOX5 (0.68) | ALOX5PTGESPPARGPPARANR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3450431-B1 | PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES | PTC THERAPEUTICS INC (US) | 2023-09-13 | — | — | EP | disclosed |
| WO-2023141804-A1 | COMPOSITION FOR BRIGHTENING OR WHITENING KERATIN MATERIALS | L'OREAL (FR) | 2023-08-03 | — | — | WO | disclosed |
| US-11673874-B2 | Synthesis of chromanol derivatives | BASF SE (DE) | 2023-06-13 | — | — | US | disclosed |
| US-11673874-B2 | Synthesis of chromanol derivatives | BASF SE (DE) | 2023-06-13 | — | — | US | disclosed |
| US-11560364-B2 | Methods for enriching alpha-tocotrienol from mixed tocol compositions | PTC THERAPEUTICS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-20220204469-A1 | PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES | PTC THERAPEUTICS, INC. | 2022-06-30 | — | — | US | disclosed |
| US-11312697-B2 | Process for the production of alpha-tocotrienol and derivatives | PTC THERAPEUTICS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11246853-B2 | Method for evaluating the ability of a composition to prevent muscle damage and fatigue; food supplement and drug | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC (FR) | 2022-02-15 | — | — | US | disclosed |
| US-20220023450-A1 | BONE MARROW-, RETICULOENDOTHELIAL SYSTEM-, AND/OR LYMPH NODE-TARGETED RADIOLABELED LIPOSOMES AND METHODS OF THEIR DIAGNOSTIC AND THERAPEUTIC USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-27 | — | — | US | disclosed |
| US-11186559-B2 | Methods for enriching alpha-tocotrienol from mixed tocol compositions | PTC THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20120130093-A1 | PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES | PTC THERAPEUTICS, INC. | 2012-05-24 | — | — | US | disclosed |
| US-8106223-B2 | Process for the production of alpha-tocotrienol and derivatives | EDISON PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106223-B2 | Process for the production of alpha-tocotrienol and derivatives | EDISON PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| EP-1270004-B1 | USE OF GAMMA-TOCOTRIENOL AS DIURETIC | EISAI R&D MAN CO LTD (JP) | 2010-06-09 | — | — | EP | disclosed |
| EP-1270004-B1 | USE OF GAMMA-TOCOTRIENOL AS DIURETIC | EISAI R&D MAN CO LTD (JP) | 2010-06-09 | — | — | EP | disclosed |
| WO-2010051277-A1 | PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES | EDISON PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105930-A1 | PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES | PTC THERAPEUTICS, INC. | 2010-04-29 | — | — | US | disclosed |
| US-20100105930-A1 | PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES | PTC THERAPEUTICS, INC. | 2010-04-29 | — | — | US | disclosed |
| US-20030139467-A1 | Diuretics containing y-tocotrienol | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-07-24 | — | — | US | disclosed |
| EP-1270004-A1 | DIURETICS CONTAINING GAMMA-TOCOTRIENOL | Eisai Co., Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11186559-B2 | Methods for enriching alpha-tocotrienol from mixed tocol compositions | TTPA, GSTO1, CCT8 | ALOX5 345/4885PTGES 64/4885PPARG 492/4885 |
| US-20220204469-A1 | PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES | TTPA, LCAT, PCTP | ALOX5 76/4885PTGES 14/4885PPARG 654/4885 |
| US-20220023450-A1 | BONE MARROW-, RETICULOENDOTHELIAL SYSTEM-, AND/OR LYMPH NODE-TARGETED RADIOLABELED LIPOSOMES AND METHODS OF THEIR DIAGNOSTIC AND THERAPEUTIC USE | KIT, LIPA, CTSA | ALOX5 2838/4885PTGES 3628/4885PPARG 3845/4885 |
| US-11246853-B2 | Method for evaluating the ability of a composition to prevent muscle damage and fatigue; food supplement and drug | GYS1, PYGM, MYOF | ALOX5 691/4885PTGES 2797/4885PPARG 414/4885 |
| US-11560364-B2 | Methods for enriching alpha-tocotrienol from mixed tocol compositions | TTPA, GSTO1, CCT8 | ALOX5 345/4885PTGES 64/4885PPARG 492/4885 |
| US-11673874-B2 | Synthesis of chromanol derivatives | CYP4A11, CYP51A1, CYP1A1 | ALOX5 2313/4885PTGES 2441/4885PPARG 2325/4885 |
| US-11312697-B2 | Process for the production of alpha-tocotrienol and derivatives | TTPA, LCAT, PCTP | ALOX5 76/4885PTGES 14/4885PPARG 654/4885 |
| US-20120130093-A1 | PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES | TTPA, LCAT, PCTP | ALOX5 76/4885PTGES 14/4885PPARG 654/4885 |
| US-20030139467-A1 | Diuretics containing y-tocotrienol | SLC26A4, SLC5A1, REN | ALOX5 170/4885PTGES 159/4885PPARG 611/4885 |
| US-20100105930-A1 | PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES | TTPA, LCAT, PCTP | ALOX5 76/4885PTGES 14/4885PPARG 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.